Y-mAbs Therapeutics (YMAB) Misses Q2 EPS by 27c

Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q2 EPS of ($0.94), $0.27 worse than the analyst estimate of ($0.67). Revenue for the quarter came in at $10.8 million versus the consensus estimate of $11.23 million.

For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.

You May Also Be Interested In

• Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
• First Commonwealth Financial (FCF) Tops Q1 EPS by 1c
• Spotify (SPOT) jumps 10% as Q1 revenue, gross margins beat Street's estimates